Pharmafile Logo

World EPA Congress 2024: ‘Shining the light on vaccine market access’ by Genesis Research Group

June 18, 2024 |  

A presentation with Katrin Nather, PhD, Associate Director, and Tijana Ignjatovic, Executive Director, Genesis Research Group. Contact solutions@genesisrg.com or visit www.genesisrg.com.

With more and more innovative vaccines and immunization strategies coming to the market, there is an increasing drive for understanding the key decision drivers for vaccine market access. However, the overall decision-making processes across markets are often ill-defined.

Through our proprietary RPR platform, we have engaged with key decision stakeholders in vaccine market access to ‘shine a light’ on key decision criteria and access processes for vaccines in order to evaluate the opportunities of novel vaccines and guide strategic market access decisions.

world epa vaccines

This content was provided by Genesis Research Group

Company Details

 Latest Content from  Genesis Research Group 

GHO Capital Acquires Genesis Research

GHO Capital Partners LLP, the European specialist investor in global healthcare, announces the acquisition of Genesis Research, a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes...

Genesis Research: What is EVID AI?

Genesis Research Announces Significant Enhancements to EVID AI, the World's Largest AI-Enabled Healthcare Literature Database for Faster, More Efficient Searches